News Ipsen

Equities

IPN

FR0010259150

Real-time Euronext Paris Other stock markets 03:48:44 2024-04-24 am EDT			5-day change	1st Jan Change
115 ^EUR	+3.23%		+8.08%	+6.58%

08:57am	Ipsen: sales up 11% in Q1	CF
Apr. 22	Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ipsen: sales up 11% in Q1	02:57am	CF
Ipsen : Q1 2024 – sales announcement (228.28 KB)	01:32am	PU
Ipsen : Q1 2024 – highlights (288.70 KB)	01:32am	PU
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance	01:01am	GL
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance	01:00am	AQ
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	Apr. 22	MT
Ipsen: collaboration agreement with Skyhawk	Apr. 22	CF
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases	Apr. 22	GL
Ipsen and Skyhawk Therapeutics Announces RNA Targeting Research Collaboration in Rare Neurological Diseases	Apr. 22	CI
Ipsen : 2023 Universal Registration Document	Apr. 18	PU
Ipsen publishes its 2023 Universal Registration Document	Apr. 17	GL
Ipsen publishes its 2023 Universal Registration Document	Apr. 17	AQ
Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	Apr. 15	CF
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen	Apr. 03	AQ
Ipsen: worldwide licensing agreement with Sutro Biopharma	Apr. 02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02	MT
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors	Apr. 02	GL
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
IPSEN : Ipsen’s underlying fundamentals remain promising	Mar. 13
Deutsche Bank Reduces Ipsen PT, Keeps Hold Rating	Feb. 16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

IPSEN : Ipsen’s underlying fundamentals remain promising

March 13, 2024 at 11:50 am EDT